HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
STX
Seagate Technology Holdings plc
STX's fundamentals are strong, but it looks expensive: trading at 29x earnings, above its usual 17x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
STX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
STX's revenue, profitability, cash flow and balance sheet are all currently strong.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
STX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.9x | $188 | -65% |
| Forward | 12x | $545 | — |
| Fair | 17x | $318 | -42% |
| Current | 29x | $545 | — |
| Expensive | 43x | $823 | +51% |
Historical ranges are pointers, not guarantees.
STX's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
STX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
STX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
STX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.99 | +147% |
| Q3 2026 | $19.06 | +145% |
| Q2 2026 | $13.90 | +105% |
| Q1 2026 | $10.54 | +51% |
| Q4 2025 | $8.84 | +60% |
| Q3 2025 | $7.79 | +101% |
| Q2 2025 | $6.77 | +328% |
| Q1 2025 | $6.96 | +$8.26 |
| Q4 2024 | $5.51 | +$9.02 |
STX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over STX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
STX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2B | +61% |
| Q2 2026 | $3.6B | +48% |
| Q1 2026 | $3.1B | +44% |
| Q4 2025 | $2.8B | +22% |
| Q3 2025 | $2.6B | +21% |
| Q2 2025 | $2.4B | +30% |
| Q1 2025 | $2.2B | +31% |
| Q4 2024 | $2.3B | +50% |
STX's revenue has grown year over year for 10 quarters in a row: $4.2B last quarter, up 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 49% | +22 points |
| Q2 2026 | 43% | +20 points |
| Q1 2026 | 32% | +12 points |
| Q4 2025 | 30% | +8.9 points |
| Q3 2025 | 26% | +7.8 points |
| Q2 2025 | 23% | +6.6 points |
| Q1 2025 | 20% | +11 points |
| Q4 2024 | 21% | +13 points |
STX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
STX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +246% |
| Q2 2026 | $1.1B | +163% |
| Q1 2026 | $953M | +341% |
| Q4 2025 | $607M | +305% |
| Q3 2025 | $427M | +1481% |
| Q2 2025 | $425M | +12% |
| Q1 2025 | $216M | +69% |
| Q4 2024 | $150M | +52% |
STX has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over STX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
STX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +3M shares |
| 1 year | +2.7% | +6M shares |
| 3 years | +12% | +24M shares |
| 5 years | +0.4% | +1M shares |
| Available history | -12% | -33M shares |
STX has 232M diluted shares, up 2.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | $117M |
| Q1 2026 | $30M |
| Q4 2025 | — |
| Q3 2025 | $29M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
STX spent $547M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
STX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.8x | Moderate |
STX's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
STX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 8.3 | Oversold |
STX's weekly RSI is 40 (neutral) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
STX PE vs Technology Sector
| Metric | STX | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 28x | 2.7% above |
| PE % | 75 | 35 | 40 pts above |
STX is trading at 29x earnings, in line with the Technology sector's median of 28x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
STX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $683.6 | 20% below |
| 20 week MA | $785.0 | 31% below |
| 50 week MA | $630.7 | 14% below |
| 100 week MA | $387.3 | 41% above |
| 200 week MA | $234.4 | 133% above |
STX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
STX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.6 | $63.0 | +5.7% |
| 2021 | $63.0 | $111.4 | +77% |
| 2022 | $111.4 | $50.5 | -55% |
| 2023 | $50.5 | $85.4 | +69% |
| 2024 | $85.4 | $87.4 | +2.4% |
| 2025 | $87.4 | $286.2 | +228% |
| 2026 YTD | $286.2 | $545.1 | +90% |
STX has the edge over HIMS on returns for 2026, with the stronger performance.